Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved complete or near complete skin clearance at three years on a single monthly ...

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

ORLANDO — Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab compared with placebo, according to a presenter at the American ...

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

in moderate to severe atopic dermatitis (AD). The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of eczema, known as atopic dermatitis, is characterized by persistent itching ...

It is more difficult to diagnose a cat with feline atopic skin syndrome than it is to diagnose a dog with atopic dermatitis, ...

In severe atopic dermatitis, erythroderma may be present as lesions coalesce into generalized areas of erythema. The skin may appear hyperpigmented or hypopigmented after the lesions heal.

"The ROCKET-Horizon trial met the co-primary and key secondary endpoints in a highly diverse, treatment-experienced, moderate-to-severe atopic dermatitis patient population," said Guttman-Yassky.